D
uring recent years, the PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) has received increasing attention as a tumour suppressor that functions by dephosphorylating and antagonizing the survival-promoting protein kinases AKT, PKC and S6K1 [1] . Previous studies reported that PHLPP1 co-localizes with the tumour suppressor Scribble at cellcell contacts [2] , its expression is lost in colorectal cancer tumours [3] and it correlates with expression of PTEN, a tumour suppressor phosphatase that functions as a negative regulator upstream from AKT [2, 4] . We warn that the PHLPP1 antibodies used in these studies (Bethyl IHC-00382 and A300-660A) crossreact strongly with β-catenin, a protooncogene product known to localize to adherens junctions.
When probing Caco-2 whole cell lys ates (WCLs) for PHLPP1 with commonly used commercial PHLPP1 antibodies (Bethyl IHC-00382 and A300-660A-different types of the same antibody), we observed an additional prominent immuno reactive band around 90 kDa (Fig 1C) , which was still apparent on PHLPP1 immunoprecipitation using the same antibodies (Fig 1A) . In contrast with full length PHLPP1, the 90 kDa band was not responsive to siRNA-mediated knockdown of PHLPP1 (Fig 1A,C) , arguing against a PHLPP1 variant and suggesting it reflected antibody cross reactivity. To characterize further this putative crossreactivity, we used stable isotope labelling in cell culture and performed quantitative tandem mass spectro metry on PHLPP1 immuno precipitates (Fig 1A) . The oncogenic WNT-signalling component β-catenin was identified as the most prominent specifically purified protein-37.5% sequence coverage compared with 4.5% for PHLPP1; data not shown-having a reported molecular weight of 90 kDa. Indeed, β-catenin comigrated with the PHLPP1 antibody crossreactivity in WCL and PHLPP1
Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β-catenin immunoprecipitates (Fig 1B,C) . Conversely, the PHLPP1 antibody strongly recognized a 90 kDa species in β-catenin immunoprecipitates, (Fig 1B) further substantiating β-catenin as the underlying crossreactivity.
To exclude alternative explanations, we performed siRNA-mediated knockdown of PHLPP1 and β-catenin. PHLPP1 antibody crossreactivity at 90 kDa was strongly reduced after β-catenin knockdown without affecting full-length PHLPP1 levels (Fig 1C) . β-catenin levels in PHLPP1 immunoprecipitates were not affected by PHLPP1 knockdown (Fig 1B) . This argued against a prominent physiological direct association of PHLPP1 and β-catenin and thus explained the immunoreactivity (Fig 1A) . Our observations were reproducible in other cell lines (HeLa and 293T), excluding the existence of Caco-2-specific artefacts. These results raise concern for the potential contaminating effects of β-catenin, a known membrane-targeted factor, for localization studies of PHLPP1. Indeed, in confluent Caco-2 cells, we observed complete co-localization of PHLPP1 (IHC-00382) with β-catenin by immunofluorescence (Fig 1D) . Strikingly, cells in which β-catenin levels had been depleted by siRNA (as indicated with an asterisk in Fig 1) lost PHLPP1 staining at cell-cell contact, whereas PHLPP1 staining remained prominent in cells that had poor β-catenin knockdown. Immunohistochemical staining of PHLPP1 and β-catenin within 5 μm sections of each other, from a tissue microarray of primary colorectal carcinomas (n = 742; [5] ), revealed a similar staining pattern with the two antibodies (Fig 1E) and, correspondingly, a non-physiologically strong correlation between PHLPP1 and β-catenin on membranes (p-value 2 × 10 -64 ; Fig 1E) and in nuclear staining (p-value 1 × 10 -14 ; Fig 1F) .
Collectively, these results confirm the strong crossreactivity of PHLPP1 antibodies Bethyl IHC-00382 and A300-660A with β-catenin, making it impossible to conclude the intra cellular localization of PHLPP1 using these antibodies. Although the cause of crossreactivity remains uncertain, we note that the PHLPP1-derived antigen used for immunization bears substantial sequential homology to the carboxyl terminus of β-catenin-74% similarity over eight amino acids.
As in situ analysis of the expression of potential biomarkers in patient tumours is used to correlate expression or localization with patient survival, it is important that the antibodies used in such studies are specific for the protein of interest. Given the localization of β-catenin and its implication in a wide variety of tumours, including those that are the focus of PHLPP1 studies, our observations strongly warn against the use of the antibodies Bethyl IHC-00382 and A300-660A in studies probing PHLPP1 function and inferring prognostic value to cellular PHLPP1 dynamics in tumour progression.
